tes; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or terminated without any further product success; and risks associated with third party intellectual property and pending or future litigation relating thereto. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2012. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise, unless required by law.
This news release and/or the financial results attached to this news release include amounts that are considered "non-GAAP financial measures" under SEC rules. As required, Regeneron has provided reconciliations of these measures.Contacts Information:Michael Aberman, M.D.
Peter DworkinInvestor Relations
email@example.com TABLE 1REGENERON PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
(In thousands)March 31,December 31,20132012ASSETSCash, restricted cash, and marketable securities$
587,511Accounts receivable - trade, net703,857593,207Accounts
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1
|SOURCE Regeneron Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence2
. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody3
. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet4
. Regeneron Announces March 2012 Investor Conference Presentations5
. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference6
. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results7
. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results8
. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results9
. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development10
. InterMune Reports First Quarter 2013 Financial Results and Business Highlights11
. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com